Neuropediatrics 1992; 23(3): 123-125
DOI: 10.1055/s-2008-1071326
Original article

© Georg Thieme Verlag KG Stuttgart · New York

Immunotherapy with Stimulated Autologous Lymphocytes in a Case of a Juvenile Anaplastic Glioma*

C.  Thomas1 , R.  Schober1 , H. G. Lenard2 , C. B. Lumenta3 , D. B. Jacques4 , W.  Wechsler1
  • 1Department of Neuropathology, Heinrich-Heine-University, Moorenstr. 5, Düsseldorf, Germany
  • 2Department of Pediatrics, Heinrich-Heine-University, Moorenstr. 5, Düsseldorf, Germany
  • 3Department of Neurosurgery Clinics, Heinrich-Heine-University, Moorenstr. 5, Düsseldorf, Germany
  • 4Huntington Medical Research Center, Pasadena, California, USA
* Supported by the „Deutsche Forschungsgemeinschaft”
Further Information

Publication History

Publication Date:
19 March 2008 (online)


The effect of immunotherapy with stimulated autologous lymphocytes (SAL) in malignant gliomas is documented and discussed in a bioptical and autoptical case study. A five-year-old child with a recurrently operated and radiated right hemispheric anaplastic astrocytoma died six weeks after immunotherapy with mitogen-activated killer cells and recombinant Interleukin-2. The autopsy revealed a large butterfly glioma with partially necrotic gelatinous tissue at the site of the SAL reservoir. The tumor cell density on the right was less than on the left hemisphere, and T-lymphocyte content was higher on the right hemisphere. These results demonstrate a local effect of SAL therapy in vivo, although the tumor progression as a whole could not be stopped. They also demonstrate the need of a detailed neuropathological examination in all cases of immunotherapy of malignant gliomas.